Fluorescent Biosensor Detects Alzheimer's Amyloid-Beta Peptide at Ultra-Low Concentrations

The H1GA(D45C)-NBD anticalin conjugate showed a 6-fold increase in fluorescence emission at 546 nm upon binding amyloid-beta peptides, with an ultra-high binding affinity of KD = 1.2 ± 0.8 nM. The sensor maintained its performance in the presence of 5% (w/v) albumin, demonstrating potential for use in complex biological samples. The engineering strategy involved introducing unpaired cysteine residues in the binding loop region and conjugating them with IANBD amide as a solvatochromic fluorophore — a dye whose emission changes based on its chemical environment.

Protein engineering approach where unpaired cysteine residues were introduced at seven positions within the anticalin's binding loops. Five mutants were successfully purified as monomers and conjugated with IANBD amide fluorophore. Ligand-dependent fluorescence was tested with Aβ40 and Aβ42 peptides, and binding affinity was determined. Performance was validated in the presence of 5% albumin to simulate biological fluid conditions.

Early detection of amyloid-beta peptides is crucial for Alzheimer's diagnosis and monitoring. Current methods are either invasive (cerebrospinal fluid analysis) or expensive (PET brain scans). A simple fluorescent biosensor that detects Aβ peptides in body fluids could enable earlier, cheaper, and more accessible Alzheimer's screening, particularly as new anti-amyloid drugs make early diagnosis increasingly important for treatment decisions.

As anti-amyloid therapies like lecanemab and donanemab enter clinical use, the need for accessible amyloid-beta detection methods is growing. This biosensor could complement or eventually replace more expensive diagnostic tools. The anticalin engineering platform is also notable — these engineered binding proteins are smaller and cheaper to produce than antibodies, making them attractive for diagnostic applications targeting peptide biomarkers.

This is a proof-of-concept laboratory study. The biosensor has not been tested with actual patient samples (blood or CSF). The 1.2 nM affinity is excellent, but the concentrations of Aβ peptides in blood are typically in the low picomolar range, so further sensitivity improvements may be needed for blood-based diagnostics. Interference from other proteins or molecules in clinical samples beyond albumin has not been assessed.